[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alleviant Medical, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100578533","alleviant-allay-hfref-study-100578533",false,"NCT06812533","Alleviant ALLAY-HFrEF Study","Safety and Efficacy of the Alleviant No-Implant Interatrial Shunt in Patients With Heart Failure and Reduced Ejection Fraction","Inclusion Criteria:\n\n* LVEF ≤ 40%\n* NYHA class II, III or ambulatory IV HF\n* Receiving optimal, maximally tolerated, stable GDMT\n\nExclusion Criteria:\n\n* Advanced heart failure\n* Life-expectancy \\\u003C 12 months\n* Evidence of right heart dysfunction","ALL","18 Years",{"count":19,"type":20},350,"ESTIMATED","INTERVENTIONAL",[23],"NA","Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.",[26],"Heart Failure","RECRUITING","2026-08-12",{"date":30,"type":31},"2026-08-14","ACTUAL",{"date":33,"type":31},"2025-03-10",{"date":35,"type":20},"2028-12",{"name":37,"class":38},"Alleviant Medical, Inc.","INDUSTRY",67,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":53,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},"100491912","alleviant-allay-hf-study-100491912","NCT05685303","Alleviant ALLAY-HF Study","Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients With Chronic Heart Failure","Inclusion Criteria:\n\n1. Symptomatic HFpEF\u002FHFmrEF with LVEF greater than or equal to 40%\n2. NYHA Class II, III or ambulatory IV\n3. Exercise right heart catheterization\\*\n\n   1. Elevated left atrial pressure during exercise right heart catheterization (greater than or equal to 25 mmHg)\n   2. Exercise PVR \\\u003C 1.8 WU\n4. Ongoing stable GDMT\n\nExclusion Criteria:\n\n1. Advanced heart failure\n2. Presence of a pacemaker\n3. Evidence of right heart dysfunction","40 Years",{"count":49,"type":20},700,[23],"Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF\u002FHFmrEF.",[26],{"date":30,"type":31},{"date":55,"type":31},"2023-01-10",{"date":57,"type":20},"2032-12-01",{"name":37,"class":38},93,""]